Work

A phase II trial of stenoparib (2×-121): A novel dual tankyrase and poly (ADP-ribose) polymerase inhibitor in advanced, recurrent ovarian cancer

Year: 2025

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2025.04.102

Authors: Fernanda Musa, Ursula Matulonis, Charles Drescher, Joshua Press, Laura Holman, Debra Richardson, Steen Knudsen, Jeremy Graff, Thomas Jensen, Marianne Lindorff Larsen, Annette Nielsen, Peter Gimsing, Anker Hansen, Mogens Madsen, Kathleen Moore

Institutions: Dana-Farber Cancer Institute, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Oklahoma

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414649959

FWCI:

Cites:

Cited by:

Related to: 10